A Study to Learn About Study Medicine Called PF-07261271 in Healthy People
Status and phase
Completed
Phase 1
Conditions
Healthy
Treatments
Drug: Placebo
Drug: PF-07261271
Details and patient eligibility
About
The purpose of this clinical trial is to learn about the safety and effects of the study medicine PF-07261271 for the potential treatment of Inflammatory Bowel Disease.
Enrollment
35 patients
Sex
All
Ages
18 to 65 years old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Healthy individuals as determined by medical evaluation
- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
Exclusion criteria
- Clinically significant medical conditions
- History of HIV infection, hepatitis B, or hepatitis C
- BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic)
- Clinically relevant ECG abnormalities
- Previous study drug administration within 30 days or 5 half-lives of first planned dose
- History of drug/alcohol abuse or >20 cigarettes/day
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Sequential Assignment
Masking
Double Blind
35 participants in 16 patient groups, including a placebo group
Cohort 1 active
Experimental group
Description:
Dose A
Treatment:
Drug: PF-07261271
Cohort 1 placebo
Placebo Comparator group
Description:
Dose A
Treatment:
Drug: Placebo
Cohort 2 active
Experimental group
Description:
Dose B
Treatment:
Drug: PF-07261271
Cohort 2 placebo
Placebo Comparator group
Description:
Dose B
Treatment:
Drug: Placebo
Cohort 3 active
Experimental group
Description:
Dose C
Treatment:
Drug: PF-07261271
Cohort 3 placebo
Placebo Comparator group
Description:
Dose C
Treatment:
Drug: Placebo
Cohort 4 active
Experimental group
Description:
Dose D
Treatment:
Drug: PF-07261271
Cohort 4 placebo
Placebo Comparator group
Description:
Dose D
Treatment:
Drug: Placebo
Cohort 5 active
Experimental group
Description:
Dose E
Treatment:
Drug: PF-07261271
Cohort 5 placebo
Placebo Comparator group
Description:
Dose E
Treatment:
Drug: Placebo
Cohort 6 active
Experimental group
Description:
Dose F
Treatment:
Drug: PF-07261271
Cohort 6 placebo
Placebo Comparator group
Description:
Dose F
Treatment:
Drug: Placebo
Cohort 7 active
Experimental group
Description:
Dose G
Treatment:
Drug: PF-07261271
Cohort 7 placebo
Placebo Comparator group
Description:
Dose G
Treatment:
Drug: Placebo
Cohort 8 active
Experimental group
Description:
Dose H
Treatment:
Drug: PF-07261271
Cohort 8 placebo
Placebo Comparator group
Description:
Dose H
Treatment:
Drug: Placebo
Trial contacts and locations
5
Loading...
Central trial contact
Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems